Early remission | Arm 1 | Arm 2 | OP group | |
---|---|---|---|---|
Baseline characteristics | (N = 387) | (N = 83) | (N = 78) | (N = 50) |
Mean age (±SD), years | 52 ± 14 | 48 ± 14 | 51 ± 14 | 54 ± 14 |
Females, n (%) | 239 (62) | 63 (76) | 64 (82) | 42 (84) |
Symptom duration, weeks | 17 (9 to 30) | 22 (9 to 40) | 21 (8 to 29) | 18 (9 to 42) |
ACPA-positive, n (%) | 225 (58) | 40 (48) | 36 (46) | 25 (50) |
RA2010, n (%) | 297 (77) | 66 (80) | 64 (82) | 40 (80) |
Erosive disease, n (%) | 63 (16) | 10 (12) | 13 (17) | 3 (6) |
DAS, mean ± SD | 3.0 ± 0.9 | 3.6 ± 0.9 | 3.6 ± 1.0 | 3.6 ± 0.9 |
Tender joint count, median (IQR) | 5 (2 to 9) | 6 (3 to 10) | 8 (4 to 12) | 7 (3 to 13) |
Swollen joint count, median (IQR) | 5 (3 to 8) | 8 (6 to 13) | 9 (6 to 13) | 8 (6 to 14) |
HAQ, mean ± SD | 1.0 ± 0.7 | 1.4 ± 0.6 | 1.4 ± 0.65 | 1.3 ± 0.7 |
MCS, mean ± SD | 51.2 ± 10.2 | 46.1 ± 12.4 | 48.8 ± 11.5 | 46.5 ± 13.3 |
PCS, mean ± SD | 37.6 ± 9.3 | 33.0 ± 8.8 | 32.9 ± 8.9 | 35.2 ± 8.5 |
Mean MACTAR, mean ± SD | 50.1 ± 4.5 | 47.7 ± 4.6 | 48.1 ± 4.6 | 47.7 ± 5.2 |
Mean VASgl (±SD), mm | 43 ± 24 | 54 ± 20 | 54 ± 22 | 51 ± 22 |
Mean VASda activity (±SD), mm | 56 ± 25 | 66 ± 19 | 67 ± 22 | 66 ± 20 |
Mean VASpain (±SD), mm | 50 ± 24 | 63 ± 19 | 61 ± 20 | 60 ± 24 |
Mean VASms (±SD), mm | 56 ± 27 | 69 ± 21 | 62 ± 25 | 54 ± 30 |